Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...